2018
Fallopian tube lesions in women at high risk for ovarian cancer: A multicenter study
Visvanathan K, Shaw P, May BJ, Bahadirli-Talbot A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM. Fallopian tube lesions in women at high risk for ovarian cancer: A multicenter study. Cancer Prevention Research 2018, 11: canprevres.0009.2018. PMID: 30232083, PMCID: PMC6760670, DOI: 10.1158/1940-6207.capr-18-0009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCystadenocarcinoma, SerousDisease ProgressionFallopian Tube NeoplasmsFallopian TubesFemaleHumansMedical History TakingMiddle AgedOvarian NeoplasmsOvaryPrecancerous ConditionsPrevalencePrognosisProspective StudiesRetrospective StudiesSalpingo-oophorectomyConceptsSerous tubal intraepithelial lesionsHigh-grade serous ovarian carcinomaSerous tubal intraepithelial carcinomaP53 signatureRisk/protective factorsProtective factorsMultiple lesionsFallopian tubePrognosis of womenHigh-risk womenTubal intraepithelial carcinomaTubal intraepithelial lesionsSerous ovarian carcinomaPutative precursor lesionsYears of ageIntraepithelial lesionsIntraepithelial carcinomaMulticenter studyInvasive cancerOvarian carcinomaDisease progressionPrecursor lesionsEpidemiologic dataCombined prevalenceTubal lesions
2007
IGF-I in epithelial ovarian cancer and its role in disease progression
Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H, Yu H. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007, 25: 346-354. PMID: 18236213, DOI: 10.1080/08977190701838402.Peer-Reviewed Original ResearchConceptsIGF-I transcriptsDisease progressionOvarian cancerTumor progressionEpithelial ovarian cancer patientsIGF-I mRNA expressionInsulin-like growth factorParacrine/autocrine regulationIGF-I activityEpithelial ovarian cancerIGF-I actionOvarian cancer patientsFresh tumor samplesIGF-I expressionIGF-I mRNAOvarian cancer progressionEnzyme-linked immunosorbentParacrine/autocrineTotal IGFFree IGFClinicopathologic featuresCA polymorphismCancer patientsReal-time PCRElevated risk
2006
The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.
Lu L, Katsaros D, Wiley A, de la Longrais I, Risch HA, Puopolo M, Yu H. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clinical Cancer Research 2006, 12: 1208-1214. PMID: 16489075, DOI: 10.1158/1078-0432.ccr-05-1801.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorDisease ProgressionEpithelial CellsEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IIMiddle AgedNeoplasm StagingOvarian NeoplasmsReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmSurvival AnalysisConceptsIGF-II expressionEstrogen receptor alpha expressionReceptor alpha expressionEpithelial ovarian cancerIGF-IIDisease progressionOvarian cancerInsulin-like growth factor (IGF) systemPrimary epithelial ovarian cancerProtein 3Insulin-like growth factorIGF signalingHigh IGF-IILarge residual lesionExpression of estrogenInsulin-like growth factor IIIGFBP-3 expressionEffects of IGFOvarian cancer treatmentGrowth factor systemFresh tumor specimensGrowth factor IIQuantitative reverse transcription PCRIGFBP-3Serous histology
2005
Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival
Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecologic Oncology 2005, 100: 330-337. PMID: 16199080, DOI: 10.1016/j.ygyno.2005.08.035.Peer-Reviewed Original ResearchConceptsOvarian cancer treatmentDisease progressionGSTP1 genotypesGST polymorphismsPrimary epithelial ovarian cancerCox proportional hazards regressionFunctional polymorphismsGSTP1 Ile/IleCancer treatmentGSTP1 Ile/ValGlutathione S-transferase polymorphismsGSTM1 null patientsPost-operative chemotherapySubgroup of patientsProportional hazards regressionEpithelial ovarian cancerOvarian cancer survivalEffect of chemotherapyOvarian cancer prognosisOvarian cancer progressionVal/ValIle/IleIle/ValOverall survivalTumor characteristics